JP2009509171A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009509171A5 JP2009509171A5 JP2008532365A JP2008532365A JP2009509171A5 JP 2009509171 A5 JP2009509171 A5 JP 2009509171A5 JP 2008532365 A JP2008532365 A JP 2008532365A JP 2008532365 A JP2008532365 A JP 2008532365A JP 2009509171 A5 JP2009509171 A5 JP 2009509171A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- cancer
- indicator
- chemotherapeutic agent
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 20
- 229940079593 drug Drugs 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 19
- 239000002246 antineoplastic agent Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 229940127089 cytotoxic agent Drugs 0.000 claims 10
- 230000004043 responsiveness Effects 0.000 claims 9
- 230000009257 reactivity Effects 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 229940044683 chemotherapy drug Drugs 0.000 claims 5
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960003668 docetaxel Drugs 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 229960002066 vinorelbine Drugs 0.000 claims 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
- 229940053867 xeloda Drugs 0.000 claims 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims 1
- 102000000131 Beta tubulin Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 claims 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- HBPQPBSTHOHSFP-UHFFFAOYSA-N OC(=O)C([Pt])=O Chemical compound OC(=O)C([Pt])=O HBPQPBSTHOHSFP-UHFFFAOYSA-N 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 102000006382 Ribonucleases Human genes 0.000 claims 1
- 108010083644 Ribonucleases Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229940123237 Taxane Drugs 0.000 claims 1
- 108010022394 Threonine synthase Proteins 0.000 claims 1
- 102000005497 Thymidylate Synthase Human genes 0.000 claims 1
- 108090000704 Tubulin Proteins 0.000 claims 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 229940120638 avastin Drugs 0.000 claims 1
- 208000036815 beta tubulin Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000000875 corresponding effect Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 238000000295 emission spectrum Methods 0.000 claims 1
- 229960001904 epirubicin Drugs 0.000 claims 1
- 229940082789 erbitux Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000005284 excitation Effects 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 239000011672 folinic acid Substances 0.000 claims 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims 1
- 235000008191 folinic acid Nutrition 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 229960001691 leucovorin Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000010534 mechanism of action Effects 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000012188 paraffin wax Substances 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000007619 statistical method Methods 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71872405P | 2005-09-21 | 2005-09-21 | |
| US77890106P | 2006-03-06 | 2006-03-06 | |
| PCT/US2006/036749 WO2007035842A2 (en) | 2005-09-21 | 2006-09-21 | Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012108724A Division JP2012177706A (ja) | 2005-09-21 | 2012-05-10 | 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009509171A JP2009509171A (ja) | 2009-03-05 |
| JP2009509171A5 true JP2009509171A5 (https=) | 2009-11-05 |
Family
ID=37889517
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532365A Pending JP2009509171A (ja) | 2005-09-21 | 2006-09-21 | 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験 |
| JP2012108724A Pending JP2012177706A (ja) | 2005-09-21 | 2012-05-10 | 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012108724A Pending JP2012177706A (ja) | 2005-09-21 | 2012-05-10 | 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20070071762A1 (https=) |
| EP (1) | EP1946114A4 (https=) |
| JP (2) | JP2009509171A (https=) |
| KR (1) | KR20080066663A (https=) |
| CA (1) | CA2623445A1 (https=) |
| WO (1) | WO2007035842A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2359689B1 (en) * | 2002-09-27 | 2015-08-26 | The General Hospital Corporation | Microfluidic device for cell separation and use thereof |
| US8921102B2 (en) * | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| CN103424541B (zh) | 2006-05-18 | 2018-01-30 | 分子压型学会股份有限公司 | 确定针对病状的个性化医疗介入的系统和方法 |
| EP2589668A1 (en) | 2006-06-14 | 2013-05-08 | Verinata Health, Inc | Rare cell analysis using sample splitting and DNA tags |
| EP2029779A4 (en) | 2006-06-14 | 2010-01-20 | Living Microsystems Inc | HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS |
| US20080090239A1 (en) * | 2006-06-14 | 2008-04-17 | Daniel Shoemaker | Rare cell analysis using sample splitting and dna tags |
| US20080050739A1 (en) | 2006-06-14 | 2008-02-28 | Roland Stoughton | Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats |
| US8137912B2 (en) | 2006-06-14 | 2012-03-20 | The General Hospital Corporation | Methods for the diagnosis of fetal abnormalities |
| EP2235536A4 (en) * | 2007-12-20 | 2011-05-04 | Lab Corp America Holdings | HER-2-DIAGNOSTIC PROCEDURE |
| SG192544A1 (en) * | 2008-01-31 | 2013-08-30 | Univ Keio | Marker for determination of sensitivity to anti-cancer agent |
| WO2010028288A2 (en) | 2008-09-05 | 2010-03-11 | Aueon, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| CA3069082C (en) | 2008-09-20 | 2022-03-22 | The Board Of Trustees Of The Leland Stanford Junior University | Noninvasive diagnosis of fetal aneuploidy by sequencing |
| WO2010056337A2 (en) | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
| DE102009047146B4 (de) | 2009-11-25 | 2012-07-19 | Ulrich Pachmann | Verfahren zum Vorhersagen des Ansprechens einer Tumorerkrankung auf eine therapeutische Maßnahme |
| EP2542696B1 (en) | 2010-03-01 | 2016-09-28 | Caris Life Sciences Switzerland Holdings GmbH | Biomarkers for theranostics |
| JP2013526852A (ja) | 2010-04-06 | 2013-06-27 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス | 疾患に対する循環バイオマーカー |
| JP5951603B2 (ja) | 2010-07-07 | 2016-07-13 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ | 乳がんの診断および治療 |
| EP2619329B1 (en) | 2010-09-24 | 2019-05-22 | The Board of Trustees of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target dna using immobilized primers |
| JP5900489B2 (ja) * | 2011-03-25 | 2016-04-06 | コニカミノルタ株式会社 | 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法 |
| EP2726870B1 (en) | 2011-06-29 | 2018-10-03 | Academia Sinica | The capture, purification and release of biological substance using a surface coating |
| CN102409087B (zh) * | 2011-08-11 | 2014-01-01 | 厦门艾德生物医药科技有限公司 | 一种用于测定β-微管蛋白III 基因表达的引物、探针及检测试剂盒 |
| KR101327533B1 (ko) | 2012-12-11 | 2013-11-08 | 사회복지법인 삼성생명공익재단 | 환자 맞춤형 항암제 선별용 시스템 |
| WO2014194289A1 (en) * | 2013-05-31 | 2014-12-04 | Nektar Therapeutics | Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents |
| TW201623605A (zh) | 2014-04-01 | 2016-07-01 | 中央研究院 | 用於癌症診斷及預後之方法及系統 |
| US10112198B2 (en) | 2014-08-26 | 2018-10-30 | Academia Sinica | Collector architecture layout design |
| US10746740B2 (en) | 2015-01-22 | 2020-08-18 | Konica Minolta, Inc. | Biological substance quantitation method, pathological diagnosis support system, and recording medium storing computer readable program |
| US12106213B2 (en) | 2016-02-01 | 2024-10-01 | Mitchell International, Inc. | Systems and methods for automatically determining adjacent panel dependencies during damage appraisal |
| US12190358B2 (en) | 2016-02-01 | 2025-01-07 | Mitchell International, Inc. | Systems and methods for automatically determining associations between damaged parts and repair estimate information during damage appraisal |
| US10107726B2 (en) | 2016-03-16 | 2018-10-23 | Cellmax, Ltd. | Collection of suspended cells using a transferable membrane |
| WO2019191280A1 (en) * | 2018-03-27 | 2019-10-03 | Laboratory Corporation Of America Holdings | Sandwich elisa for identifying subjects who may benefit from treatment with therapeutic agents |
| CN112082976A (zh) * | 2019-06-14 | 2020-12-15 | 天津方得生物科技有限公司 | 基于药物探针及组织切片的体外药物敏感性检测方法 |
| CN111458514A (zh) * | 2019-12-18 | 2020-07-28 | 王�琦 | 一种外周血中的肿瘤细胞株数量的检测方法 |
| CN111458515A (zh) * | 2019-12-18 | 2020-07-28 | 王�琦 | 一种外周血中的肺小细胞肿瘤细胞数量的检测方法 |
| JP7806660B2 (ja) * | 2022-11-11 | 2026-01-27 | コニカミノルタ株式会社 | 検出方法 |
| PL444462A1 (pl) * | 2023-04-18 | 2024-10-21 | Uniwersytet Medyczny W Białymstoku | Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU744095B2 (en) * | 1997-03-27 | 2002-02-14 | Baker Norton Pharmaceuticals, Inc. | Methods and compositions for treatment of ovarian cancer |
| EP1283904A2 (en) * | 1999-11-03 | 2003-02-19 | Oncotech, Inc. | Cancer diagnosis using cell-sorting and gene-expression-profiles |
| EP1286671B1 (en) * | 2000-05-15 | 2006-04-05 | Celgene Corporation | Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan |
| DE10043591A1 (de) * | 2000-09-01 | 2002-03-14 | Max Delbrueck Centrum | Verfahren zur Erfassung von Resistenz-Profilen von Geweben und Zellinien |
| ES2374311T3 (es) * | 2002-03-13 | 2012-02-15 | Genomic Health, Inc. | Obtención de perfil de expresión génica en tejidos tumorales biopsiados. |
| US20030190689A1 (en) * | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
| ES2542328T3 (es) * | 2002-12-06 | 2015-08-04 | Millennium Pharmaceuticals, Inc. | Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma |
| WO2004052184A2 (en) * | 2002-12-12 | 2004-06-24 | Oncotech, Inc. | Genes related to sensitivity and resistance to chemotherapeutic drug treatment |
| EP1649052A1 (en) * | 2003-08-01 | 2006-04-26 | The University Of Western Australia | Methods and kits for predicting the likelihood of successful treatment of cancer |
| EP1697751A2 (en) * | 2003-12-04 | 2006-09-06 | Ludwig Institute For Cancer Research | Assay and treatment |
| WO2006055676A2 (en) * | 2004-11-16 | 2006-05-26 | The Uab Research Foundation | Molecular basis for the identification of chemotherapy resistance in human tumors and the treatment thereof |
-
2006
- 2006-09-21 CA CA002623445A patent/CA2623445A1/en not_active Abandoned
- 2006-09-21 US US11/533,929 patent/US20070071762A1/en not_active Abandoned
- 2006-09-21 WO PCT/US2006/036749 patent/WO2007035842A2/en not_active Ceased
- 2006-09-21 KR KR1020087006823A patent/KR20080066663A/ko not_active Withdrawn
- 2006-09-21 JP JP2008532365A patent/JP2009509171A/ja active Pending
- 2006-09-21 EP EP06815067A patent/EP1946114A4/en not_active Withdrawn
-
2012
- 2012-05-10 JP JP2012108724A patent/JP2012177706A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009509171A5 (https=) | ||
| Loi et al. | The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition | |
| Nicolle et al. | A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma | |
| Szymiczek et al. | Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review | |
| JP6787976B2 (ja) | 細胞全体でのアッセイおよび方法 | |
| Yamasaki et al. | Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma | |
| Demonty et al. | Progress and new standards of care in the management of HER-2 positive breast cancer | |
| Zhao et al. | ABCC3 as a marker for multidrug resistance in non-small cell lung cancer | |
| JP6782698B2 (ja) | がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法 | |
| Sheri et al. | Developments in Ki67 and other biomarkers for treatment decision making in breast cancer | |
| Generali et al. | Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer | |
| CN113025713A (zh) | 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用 | |
| Hadžisejdić et al. | Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis | |
| Kaira et al. | The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy | |
| Fisher et al. | An analysis of human equilibrative nucleoside transporter‐1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross‐complementing gene‐1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment | |
| Zheng et al. | Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer | |
| JP2009509171A (ja) | 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験 | |
| Yonemori et al. | Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast | |
| Park et al. | ER and PR Immunohistochemistry and HER 2 FISH versus Oncotype DX: Implications for Breast Cancer Treatment | |
| d‘Amato et al. | Chemotherapy resistance and oncogene expression in non–small cell lung cancer | |
| Park et al. | A seven‐gene signature can predict distant recurrence in patients with triple‐negative breast cancers who receive adjuvant chemotherapy following surgery | |
| Portier et al. | HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma | |
| US20230047712A1 (en) | Methods of Treatments Based Upon Molecular Response to Treatment | |
| Ataseven et al. | HER2/neu, topoisomerase 2a, estrogen and progesterone receptors: discordance between primary breast cancer and metastatic axillary lymph node in expression and amplification characteristics | |
| Tsuda | HER-2 (c-erbB-2) test update: present status and problems |